Changes in complement C3 levels following treatment of patients with Brugia malayi infection.
Identifieur interne : 005F91 ( PubMed/Curation ); précédent : 005F90; suivant : 005F92Changes in complement C3 levels following treatment of patients with Brugia malayi infection.
Auteurs : M. Yadav [Malaisie]Source :
- The Southeast Asian journal of tropical medicine and public health [ 0125-1562 ] ; 1989.
Descripteurs français
- KwdFr :
- Adulte, Animaux, Antihelminthiques (usage thérapeutique), Brugia, Complément C3 (analyse), Filaricides (usage thérapeutique), Filariose lymphatique (immunologie), Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Filarioses (traitement médicamenteux), Humains, Lymphadénite (traitement médicamenteux), Lymphangite (traitement médicamenteux).
- MESH :
- analyse : Complément C3.
- immunologie : Filariose lymphatique.
- sang : Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique, Filarioses, Lymphadénite, Lymphangite.
- usage thérapeutique : Antihelminthiques, Filaricides.
- Adulte, Animaux, Brugia, Humains.
English descriptors
- KwdEn :
- Adult, Animals, Anthelmintics (therapeutic use), Brugia, Complement C3 (analysis), Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Filariasis (drug therapy), Filaricides (therapeutic use), Humans, Lymphadenitis (drug therapy), Lymphangitis (drug therapy).
- MESH :
- chemical , analysis : Complement C3.
- chemical , therapeutic use : Anthelmintics, Filaricides.
- blood : Elephantiasis, Filarial.
- drug therapy : Elephantiasis, Filarial, Filariasis, Lymphadenitis, Lymphangitis.
- immunology : Elephantiasis, Filarial.
- Adult, Animals, Brugia, Humans.
Abstract
Serum IgG levels and complement C3 levels were assayed on Day 0, 1, 3-4, 7 and 56-70 post-treatment with diethylcarbamizine citrate (DEC) in a series to 26 patients with Brugia malayi infection and 6 volunteers without infection. On treatment, the microfilariae were cleared from the blood within 24 hours. The eosinophils decreased dramatically on Day 1 post-treatment but increased rapidly by Day 4 to 7 and then dropped to normal levels in 45 days. The serum IgG mean levels decreased briefly following treatment with DEC but then returned to original levels. However, the complement C3 levels gradually increased over the 2 months period of study reaching statistical significance levels (p less than 0.01) in patients with initial high blood microfilariae. The observation suggests that Brugia malayi infection probably induces a high rate of synthesis of complement C3 and this process continued in the post-treatment phase. Since, DEC treatment did not cause a decrease in complement C3 with the elimination of blood microfilariae, it would appear that the complement C3 is consumed following antibody attachment to the microfilariae as they enter the blood circulation.
PubMed: 2609207
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005F91
Links to Exploration step
pubmed:2609207Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in complement C3 levels following treatment of patients with Brugia malayi infection.</title><author><name sortKey="Yadav, M" sort="Yadav, M" uniqKey="Yadav M" first="M" last="Yadav">M. Yadav</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2609207</idno><idno type="pmid">2609207</idno><idno type="wicri:Area/PubMed/Corpus">005F91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005F91</idno><idno type="wicri:Area/PubMed/Curation">005F91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005F91</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Changes in complement C3 levels following treatment of patients with Brugia malayi infection.</title><author><name sortKey="Yadav, M" sort="Yadav, M" uniqKey="Yadav M" first="M" last="Yadav">M. Yadav</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Southeast Asian journal of tropical medicine and public health</title><idno type="ISSN">0125-1562</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Anthelmintics (therapeutic use)</term><term>Brugia</term><term>Complement C3 (analysis)</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (immunology)</term><term>Filariasis (drug therapy)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Lymphadenitis (drug therapy)</term><term>Lymphangitis (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Antihelminthiques (usage thérapeutique)</term><term>Brugia</term><term>Complément C3 (analyse)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (immunologie)</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filarioses (traitement médicamenteux)</term><term>Humains</term><term>Lymphadénite (traitement médicamenteux)</term><term>Lymphangite (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Complement C3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anthelmintics</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Complément C3</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Filariasis</term><term>Lymphadenitis</term><term>Lymphangitis</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Filarioses</term><term>Lymphadénite</term><term>Lymphangite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihelminthiques</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Brugia</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Brugia</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Serum IgG levels and complement C3 levels were assayed on Day 0, 1, 3-4, 7 and 56-70 post-treatment with diethylcarbamizine citrate (DEC) in a series to 26 patients with Brugia malayi infection and 6 volunteers without infection. On treatment, the microfilariae were cleared from the blood within 24 hours. The eosinophils decreased dramatically on Day 1 post-treatment but increased rapidly by Day 4 to 7 and then dropped to normal levels in 45 days. The serum IgG mean levels decreased briefly following treatment with DEC but then returned to original levels. However, the complement C3 levels gradually increased over the 2 months period of study reaching statistical significance levels (p less than 0.01) in patients with initial high blood microfilariae. The observation suggests that Brugia malayi infection probably induces a high rate of synthesis of complement C3 and this process continued in the post-treatment phase. Since, DEC treatment did not cause a decrease in complement C3 with the elimination of blood microfilariae, it would appear that the complement C3 is consumed following antibody attachment to the microfilariae as they enter the blood circulation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2609207</PMID><DateCreated><Year>1990</Year><Month>02</Month><Day>13</Day></DateCreated><DateCompleted><Year>1990</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-1562</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>1989</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Southeast Asian journal of tropical medicine and public health</Title><ISOAbbreviation>Southeast Asian J. Trop. Med. Public Health</ISOAbbreviation></Journal><ArticleTitle>Changes in complement C3 levels following treatment of patients with Brugia malayi infection.</ArticleTitle><Pagination><MedlinePgn>183-7</MedlinePgn></Pagination><Abstract><AbstractText>Serum IgG levels and complement C3 levels were assayed on Day 0, 1, 3-4, 7 and 56-70 post-treatment with diethylcarbamizine citrate (DEC) in a series to 26 patients with Brugia malayi infection and 6 volunteers without infection. On treatment, the microfilariae were cleared from the blood within 24 hours. The eosinophils decreased dramatically on Day 1 post-treatment but increased rapidly by Day 4 to 7 and then dropped to normal levels in 45 days. The serum IgG mean levels decreased briefly following treatment with DEC but then returned to original levels. However, the complement C3 levels gradually increased over the 2 months period of study reaching statistical significance levels (p less than 0.01) in patients with initial high blood microfilariae. The observation suggests that Brugia malayi infection probably induces a high rate of synthesis of complement C3 and this process continued in the post-treatment phase. Since, DEC treatment did not cause a decrease in complement C3 with the elimination of blood microfilariae, it would appear that the complement C3 is consumed following antibody attachment to the microfilariae as they enter the blood circulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Thailand</Country><MedlineTA>Southeast Asian J Trop Med Public Health</MedlineTA><NlmUniqueID>0266303</NlmUniqueID><ISSNLinking>0125-1562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002009" MajorTopicYN="N">Brugia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005368" MajorTopicYN="N">Filariasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008199" MajorTopicYN="N">Lymphadenitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008205" MajorTopicYN="N">Lymphangitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2609207</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F91 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 005F91 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:2609207
|texte= Changes in complement C3 levels following treatment of patients with Brugia malayi infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:2609207" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |